Skip to main content
. 2018 Apr 17;9(29):20476–20489. doi: 10.18632/oncotarget.24944

Figure 5. Lenalidomide maintenance therapy does not enhance MM-specific CD4+ T-cell responses.

Figure 5

Analysis of T-cell responses specific for the MAGE-C1 peptide SQSSPVSSFPSSTSS. (A) CD137 expression on CD4+ and CD8+ T cells from patient#02 at the pre LEN timepoint upon in vitro restimulation with the MAGE-C1 peptide. (B) PBMCs obtained at the pre LEN and the LEN timepoint were examined by IFN-γ ELISPOT to measure the T-cell response to the MAGE-C1 peptide. The bar graphs show the mean number of spots per million cells of four replicate wells and the error bars represent the standard deviation. A two-way ANOVA with Sidak’s multiple comparisons test was performed to evaluate statistical significant differences, ns: not significant, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.